Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center.

ABSTRACT:

Introduction/aims

Neonatal Fc receptor (FcRn) inhibitors represent a promising treatment option for patients with generalized myasthenia gravis (gMG); however, data on clinical use are limited. The aim of this report is to describe one center's approach to efgartigimod dosing in patients with gMG.

Methods

Medical records of patients with acetylcholine receptor antibody-positive (AChR-Ab+) gMG whose symptoms were not adequately controlled by oral medications and/or intravenous immunoglobulin who received efgartigimod between January 2022 and January 2024 were retrospectively evaluated. The first three efgartigimod cycles (10 mg/kg IV) were initiated at fixed intervals (4 once-weekly infusions, with 4 weeks between cycles). After the third cycle, initiation of subsequent treat

SUBMITTER: Silvestri NJ 

PROVIDER: S-EPMC11799394 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature